Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series - Quiz - MDSpire

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

  • By

  • Sandra Susanibar-Adaniya

  • Benjamin A. Derman

  • Adam D. Cohen

  • Dan T. Vogl

  • Shambavi Richard

  • Adriana Rossi

  • Matthew J. Frigualt

  • Andrew J. Yee

  • Binod Dhakal

  • Noffar Bar

  • April 28, 2026

  • 0 min

Share

Original Source(s)

Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series

  • by Sandra Susanibar-Adaniya, Benjamin A. Derman, Adam D. Cohen, Dan T. Vogl, Shambavi Richard, Adriana Rossi, Matthew J. Frigualt, Andrew J. Yee, Binod Dhakal, Noffar Bar

  • April 28, 2026

Related Content

AstraZeneca Deepens China Cell Therapy Push

New Shanghai manufacturing base and innovation center will support CAR-T production and a broader UK-China life sciences collaboration

  • March 31, 2026

  • 2 min
Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature

Understanding the Role of Regulatory T Cells in the Immune Microenvironment of Multiple Myeloma and Its Clinical Implications